TUBOCURARINE CHLORIDE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tubocurarine chloride is a neuromuscular blocking agent (NMBA) administered via injection for use during anesthesia and surgery. It works by competitively binding to acetylcholine receptors at the neuromuscular junction, causing muscle paralysis. This agent facilitates intubation and surgical access by providing controlled skeletal muscle relaxation.
LOE Approaching
With LOE approaching on a 77-year-old drug, brand teams are likely in defensive maintenance mode with minimal growth investment and smaller team structures focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on tubocurarine chloride offers limited career growth opportunities given zero linked job openings and its LOE-approaching status. This role is best suited for professionals seeking stability in a niche, mature product area or those transitioning to newer pipeline assets.
Brand ManagerProduct Manager
Worked on TUBOCURARINE CHLORIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.